Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: jackie who wrote (2322)	11/2/1998 10:32:00 AM
From: jopawa	Read Replies (1) \| Respond to of 4676

I caught this from thestreet.com ISIS Pharmaceuticals Michael Murphy (10/26) There's a big opportunity in ISIS Pharmaceuticals (ISIP:Nasdaq), says Michael Murphy of California Technology Stock Letter. The company recently received the green light from the Food and Drug Administration to market Vitravene, its new antisense drug. The FDA approval would mark Vitravene as the first such product to hit the marketplace. Vitravene attacks CMV retinitis, a malady that affects many AIDS patients with depressed immune deficiency systems. Murphy adds that the approval came three weeks earlier than expected and that the drug will hit the market "shortly."